[
  {
    "ts": "2025-08-13T21:50:46+00:00",
    "headline": "Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth",
    "url": "https://finance.yahoo.com/news/biogen-moderna-align-technology-quidelortho-215046236.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "19a308dc-2440-3bdf-a2fa-8a36968e5bac",
      "content": {
        "id": "19a308dc-2440-3bdf-a2fa-8a36968e5bac",
        "contentType": "STORY",
        "title": "Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know",
        "description": "",
        "summary": "A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth",
        "pubDate": "2025-08-13T21:50:46Z",
        "displayTime": "2025-08-13T21:50:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-moderna-align-technology-quidelortho-215046236.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-moderna-align-technology-quidelortho-215046236.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "ALGN"
            },
            {
              "symbol": "QDEL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-13T03:48:18+00:00",
    "headline": "BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/biib-q2-deep-dive-launches-034818545.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "297e9a64-cee9-30d3-9187-625061b58cb5",
      "content": {
        "id": "297e9a64-cee9-30d3-9187-625061b58cb5",
        "contentType": "STORY",
        "title": "BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance",
        "description": "",
        "summary": "Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates.",
        "pubDate": "2025-08-13T03:48:18Z",
        "displayTime": "2025-08-13T03:48:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biib-q2-deep-dive-launches-034818545.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biib-q2-deep-dive-launches-034818545.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-13T03:46:50+00:00",
    "headline": "5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call",
    "summary": "Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was met with a positive market reaction. Management highlighted continued growth from newly launched products, which offset ongoing declines in the multiple sclerosis portfolio. CEO Christopher Viehbacher emphasized the “strength of VUMERITY” and the “consistent growth with LEQEMBI,” noting these were key contributors to the quarter. Product expansion in rare diseases and neu",
    "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-biogen-034650026.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "13134a1f-4be4-349e-98c7-4b0c03ff12e3",
      "content": {
        "id": "13134a1f-4be4-349e-98c7-4b0c03ff12e3",
        "contentType": "STORY",
        "title": "5 Revealing Analyst Questions From Biogen’s Q2 Earnings Call",
        "description": "",
        "summary": "Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was met with a positive market reaction. Management highlighted continued growth from newly launched products, which offset ongoing declines in the multiple sclerosis portfolio. CEO Christopher Viehbacher emphasized the “strength of VUMERITY” and the “consistent growth with LEQEMBI,” noting these were key contributors to the quarter. Product expansion in rare diseases and neu",
        "pubDate": "2025-08-13T03:46:50Z",
        "displayTime": "2025-08-13T03:46:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-biogen-034650026.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-revealing-analyst-questions-biogen-034650026.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-13T02:30:00+00:00",
    "headline": "[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision",
    "url": "https://finance.yahoo.com/news/latest-us-personalized-medicine-market-023000015.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "111b19cb-db59-3d93-937d-dc0f500108fa",
      "content": {
        "id": "111b19cb-db59-3d93-937d-dc0f500108fa",
        "contentType": "STORY",
        "title": "[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
        "description": "",
        "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision",
        "pubDate": "2025-08-13T02:30:00Z",
        "displayTime": "2025-08-13T02:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891",
          "originalWidth": 2514,
          "originalHeight": 1281,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CrZC42kgw2SjdY2CY6ucw--~B/aD0xMjgxO3c9MjUxNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 2514,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91DUI4_rVm8Et9pJYV6I4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0bec09301614ea6a3ee415db83086891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/latest-us-personalized-medicine-market-023000015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/latest-us-personalized-medicine-market-023000015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ILMN"
            },
            {
              "symbol": "DHR"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "IBM"
            },
            {
              "symbol": "XGN"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]